This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $66.73, moving -0.58% from the previous trading session.
The Zacks Analyst Blog Highlights: BioTelemetry, Navios Maritime Partners, RH, TripAdvisor and eGain
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioTelemetry, Navios Maritime Partners, RH, TripAdvisor and eGain
January Marks a Good Start for Wall Street: 5 Picks
by Tirthankar Chakraborty
Traders are not only counting on the 'January effect' to push stocks higher but also this January comes in the third year of presidential election cycles, which bodes well for equities.
The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase
by Zacks Equity Research
The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase
Bull or Bear: Your Investment Strategy for 2019
by Sejuti Banerjea
Whether you're a bull or a bear, it may be a good idea to go defensive about now.
What's in Store for Teladoc in 2019, After a Strong 2018?
by Zacks Equity Research
Teladoc (TDOC) should continue to gain from increasing demand for its services and global expansion.
Cigna Poised for Growth in 2019 on Express Scripts Buyout
by Zacks Equity Research
The purchase of Express Scripts by Cigna (CI) has diversified its business, which should fuel long-term growth.
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Computer Programs and Systems, BioTelemetry, HMS, Amedisys and Molina Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Computer Programs and Systems, BioTelemetry, HMS, Amedisys and Molina Healthcare
5 Great Healthcare Stocks to Buy for 2019
by Swarup Gupta
Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.
BioTelemetry (BEAT) Stock Moves -0.56%: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed at $59.05 in the latest trading session, marking a -0.56% move from the prior day.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
Zacks.com featured highlights include: Spirit Airlines, Middlesex Water, Amedisys, BioTelemetry and Great Lakes Dredge & Dock
by Zacks Equity Research
Zacks.com featured highlights include: Spirit Airlines, Middlesex Water, Amedisys, BioTelemetry and Great Lakes Dredge & Dock
Highlighted as Zacks Bull and Bear of the Day BioTelemetry, Papa John's, Twitter and NRG Energy
by Zacks Equity Research
Highlighted as Zacks Bull and Bear of the Day BioTelemetry, Papa John's, Twitter and NRG Energy
5 Stocks With Recent Price Strength to Enhance Your Return
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Bull of the Day: BioTelemetry (BEAT)
by Kevin Cook
One of the strongest little stocks of the correction just survived a big move by Apple onto its turf
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
Teladoc (TDOC) Surges 64% in a Year: Can the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) is poised to grow on accelerating demand for its telehealth services.
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Express Scripts (ESRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PRA Health Sciences (PRAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
PRA Health Sciences (PRAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioTelemetry (BEAT) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioTelemetry (BEAT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in BioTelemetry, Inc. (BEAT).
BioTelemetry, Ultra Clean, NVIDIA and AMD highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
BioTelemetry, Ultra Clean, NVIDIA and AMD highlighted as Zacks Bull and Bear of the Day
Bull of the Day: BioTelemetry (BEAT)
by Kevin Cook
True to its name, this maker of cardiac monitoring devices and services just beat EPS by 65%